NCT06853886Recruiting
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
Source: ClinicalTrials.gov · Last updated 20 May 2026
Brief summary (registry, in English)
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 25 Feb 2025
- Start date
- 12 Aug 2025
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- University Hospital, Limoges
- Diseases
- Hepatitis B
- NCT number
- NCT06853886
What you commit to
- Study type: Interventional
- Planned participants: 140
- From 12 Aug 2025 to the primary completion date, 1 Oct 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Co-infection with HCV, HIV or HDV (or HBV for healthy volunteer)
- Acute hepatitis in the year preceding recruitment
- Other liver diseases : alcohol, obesity (BMI\>30), diabetes, metabolic syndrome (dyslipidemia and/or known hypertension) - Underlying immunological or cancerous diseases
- Positive HCV, HIV or HDV test in a patient
- Positive HBV, HCV, HIV or HDV test in a healthy volunteer
Other
- Patient with a disability that prevents him/her from fully understanding the requirements of the trial - Patient under court protection, guardianship or curatorship
- Pregnant or breast-feeding women.
- Secondary exclusion criteria:
- A healthy volunteer whose vaccination status does not match that expected on the basis of serological results
- Positive blood pregnancy test on inclusion
Who the study is looking for
- Male or female, age ≥18 years old
- HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog
- Willing and able to provide written informed consent
- Affiliated with a social securityregimen
- Healthy volunteer must meet all of the following inclusion criteria to be eligible for participation in this study:
- Male or female, age between 18 and 80 years
- Willing and able to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Limoges university hospital Coordinator of this site? Confirm its status | Limoges | France | Recruiting |
| Centre d'Investigation Clinique Coordinator of this site? Confirm its status | Limoges | France | Recruiting |
| Hospice civils de Lyon Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.